Back to Journals » Patient Preference and Adherence » Volume 8

Alitretinoin for the treatment of severe chronic hand eczema

Authors King T, McKenna J, Alexandroff A

Received 19 November 2013

Accepted for publication 26 February 2014

Published 25 November 2014 Volume 2014:8 Pages 1629—1634


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 4

Thomas King, John McKenna, Anton B Alexandroff

Department of Dermatology, University Hospitals of Leicester, Leicester Royal Infirmary, Leicester, UK

Abstract: Chronic hand eczema is a common and often debilitating condition. Alitretinoin, a 9-cis-retinoic acid and pan-retinoic acid agonist, is a new and effective systemic treatment for chronic hand eczema, which provides another treatment option. A “clear” or “almost clear” response can be achieved in up to half of patients within a 24-week course of treatment. Even higher rates of remission can be obtained with a longer duration of treatment. Alitretinoin has a favorable overall profile of adverse effects; however, female patients who are at risk of becoming pregnant should follow a strict pregnancy-prevention program due to the teratogenic effects of this drug.

Keywords: dermatitis, toctino, CTCL

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]